Sun Pharmaceutical Industries Ltd has announced the launch of Ilumya (tildrakizumab-asmn), its plaque psoriasis treatment drug, in the United States (US) market.
Ilumya in the strength of 100 mg/mL has been introduced in the US for the treatment of moderate-to-severe psoriasis.
Abhay Gandhi, Sun Pharma North America CEO, said, "The availability of Ilumya is an important milestone for Sun Pharma as we expand our specialty medicine portfolio in the US."
"Ilumya offers a new, safe and effective treatment option for people who are still struggling to manage their moderate-to-severe plaque psoriasis. We understand the importance of patient and physician choice, and are committed to making Ilumya among the most cost-effective treatments in the market today," Gandhi added.
Sun Pharma is also working closely with relevant stakeholders for ensuring that Ilumya is accessible to the patients across the US.
